Flexible vaccine assembly and vaccine delivery platform
View Patent ↗Herein-described are various methods for making a vaccine that are made of re-assembled virus like particles (VLP). First, the VLPs are disassembled into encapsidation intermediate populations. Each encapsidation intermediate population undergoes, for instance, chemical conjugation of unique peptide or nucleic moieties to form separate populations. Thereafter, a predetermined amount of each of the several (one or more) different encapsidation intermediates from the different populations is mixed and joined, forming intact VLPs, surrounding a nucleic acid core, that are composed of different encapsidation intermediate such that the reassembled VLP displays more than one peptide or nucleic acid. The nucleic acid can function either as a scaffold alone or can be engineered for the expression of an immunomodulatory protein in a eukaryotic cell.
1. A method for making a virus-like particle (VLP) containing multiple, different composition peptides or proteins displayed by a process comprising the steps of: a) disassembling separate VLP populations, each displaying a distinct peptide or protein via genetic fusion; b) disassembling a separate VLP population that has a surface residue for chemical conjugation, provided by genetic fusion; c) forming encapsidation intermediate populations such that: i) each displays a distinct peptide or protein and ii) each displays a surface residue for chemical conjugation; d) effecting chemical conjugation of unique peptide, protein or nucleic acid moieties to separate populations of the encapsidation intermediate displaying surface residue for chemical conjugation; e) mixing encapsidation intermediates from different populations displaying peptides or proteins by genetic fusion or displaying peptides, proteins or nucleic acids by chemical conjugation; f) forming intact VLP surrounding a nucleic acid core that is composed of different encapsidation intermediates such that the VLP displays more than one moiety, be it peptide, protein or nucleic acid, or some combination of these moieties.
2. A method as set forth in claim 1 , wherein the VLPs are TMV virus and the encapsidation intermediates are 20S disks.
3. A method as set forth in claim 1 , wherein the chemical conjugation of unique peptide and/or nucleic acid moieties to the encapsidation intermediates, displaying the residues for chemical conjugations, is performed following the formation of an intact VLP surrounding a nucleic acid core.